Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Barbara Winograd

Psychiatry Metuchen, NJ Medical Doctor

NPI 1750442216 CMS profile 306110

280 Amboy Ave, Metuchen, NJ 08840

Open in the dashboard

General payments

$14,192

378 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Barbara Winograd of Metuchen, NJ is reported in the CMS Open Payments database as having received $14,192 across 378 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $90 6
2022 General $405 29
2021 General $1,576 31
2020 General $3,799 75
2019 General $8,322 237

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Barbara Winograd
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Barbara Winograd were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Barbara Winograd Psychiatry median Middle half National median
2019 $8,322 $184 $59–$605 $163
2020 $3,799 $119 $36–$372 $114
2021 $1,576 $143 $43–$576 $132
2022 $405 $153 $50–$590 $149
2023 $90 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Allergan Inc. $8,997 61 payments
  2. AbbVie, Inc. $1,334 30 payments
  3. Sunovion Pharmaceuticals Inc. $535 33 payments
  4. Otsuka America Pharmaceutical, Inc. $530 51 payments
  5. Neos Therapeutics, LP $444 46 payments
  6. Validus Pharmaceuticals LLC $369 16 payments
  7. Lundbeck LLC $306 24 payments
  8. Vanda Pharmaceuticals Inc. $254 21 payments
  9. Neurocrine Biosciences, Inc. $248 12 payments
  10. Bausch Health US, LLC $200 15 payments
  11. Other $975 69 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $9,425 8 payments
  2. Food and Beverage $4,767 370 payments
Products named General payments · program years 2019–2023
  1. VRAYLAR Neuroscience $8,979 59 payments
  2. VRAYLAR Neuroscience $1,334 30 payments
  3. LATUDA $535 33 payments
  4. Adzenys XR-ODT $444 46 payments
  5. COTEMPLA XR-ODT $444 46 payments
  6. REXULTI $411 41 payments
  7. Equetro $369 16 payments
  8. HETLIOZ $254 21 payments
  9. FANAPT $254 21 payments
  10. INGREZZA $220 10 payments
  11. Other $1,947 144 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

378 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record